This last year has been a milestone in our fight against FIP. We extended our landmark studies of 2018 when we published on a collaborative study with colleagues at Kansas State University on a drug called GC376. This was the first drug to successfully cure cats of FIP. In this last year, we reported on a second antiviral drug and its safety and efficacy for the treatment of cats with naturally occurring FIP. This study, which was reported in the April issue of the Journal of Feline Medicine and Surgery, involved a small molecule viral RNA inhibitor called GS-441524. GS-441524 was developed by Gilead Sciences, Inc as part of their research into human RNA virus disease such as Ebola. We initiated this collaboration several years ago with great optimism. Over two years of laboratory work led us to the point of conducting a field trial with owned cats suffering from FIP. This initial field trial did not accept cats with definite neurological involvement based on the difficulty in treating such cats with GC376. GS-441524 proved to be even more potent against FIP and provided hints that even neurological FIP was treatable. Subsequent, and yet to be published, trials with GS-441524 on 4 cats with severe neurological and/or ocular disease have shown GS to be also effective in these most difficult cases if the drug is given at a high enough dosage.